Phospholipid Antiviral Compounds for Broad-Spectrum Viral Entry Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective compounds and methods to treat viral infections caused by Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, Arenaviridae, Orthomyxovirus, and Coronaviridae.
Innovation Solution
Development of phospholipid compounds of Formula I and their pharmaceutically acceptable salts, which can be administered to treat or prevent viral infections by reversing, alleviating, or inhibiting the progression of such disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional treatments for viral infections are used, then existing antiviral medications can treat some viral infections, but they are ineffective against multiple virus families including Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, Arenaviridae, Orthomyxovirus, and Coronaviridae
Solution Approach 1:
The phospholipid compound of Formula I is designed to function as a broad-spectrum antiviral agent effective against multiple virus families including Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, Arenaviridae, Orthomyxovirus, and Coronaviridae. The compound's structure enables it to interfere with viral fusion and entry mechanisms that are conserved across these diverse virus families, providing universal protection against multiple pathogens with a single agent.
2Adaptability or versatility
If new phospholipid compounds are developed to achieve broad-spectrum antiviral activity, then treatment effectiveness against multiple viruses improves, but the complexity of compound design and synthesis increases
Solution Approach 1:
The phospholipid compound employs specific parameter ranges in its molecular structure to achieve broad-spectrum antiviral activity. The alkyl chains at positions R1 and R1A are constrained to specific length ranges (C1-C20 and C1-C3 respectively), the integer m is limited to 10-21, and the heterocyclic or aromatic groups are restricted to specific types. These parameter constraints simplify the design space while maintaining effectiveness against multiple virus families.
Solution Approach 2:
The compound integrates multiple functional components into a single phospholipid structure: a phospholipid backbone, specific alkyl chain lengths, heterocyclic or aromatic groups, and carboxylic acid moieties. This composite structure combines properties that enable broad-spectrum antiviral activity while maintaining a manageable level of synthetic complexity through modular assembly of well-defined components.
Data Source
AI summary
Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.